drugset
drugset / Trial / NCT04900350

A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

NCT04900350 ↗

Phase 1/2 Active not recruiting 136 enrolled Akeso
NaSingle-groupOpen-labelTreatment

Summary

This is a open label, phase I/II study. All patients are diagnosed with higher-risk MDS, Eastern Cooperative Oncology Group (ECOG) performance status 0-2. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine in subjects with higher-risk MDS.

Timeline

Start
2021-06-18
Primary completion
2025-09
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AK117 Monoclonal antibody — Intravenous
Background Azacitidine Other / unclassified 75 mg/m2 Subcutaneous

Indications

myelodysplastic syndrome